Specific

abemaciclib (Verzenio) cyclin dependent kinase inhibitor-2C (ink4C) cyclin-dependent kinase 4 inhibitor B; p14-INK4b; p15-INK4b; p15INK4B; multiple tumor suppressor 2; MTS-2 (CDKN2B, MTS2) cyclin-dependent kinase 4 inhibitor C; p18-INK4c; cyclin-dependent kinase 6 inhibitor; p18-INK6 (CDKN2C, CDKN6) cyclin-dependent kinase 4 inhibitor D; CDK inhibitor-2D; p19-INK4d (CDKN2D) cyclin-dependent kinase inhibitor 1; p21WAF1/CIP1; p21; CDK-interacting protein 1; melanoma differentiation-associated protein 6; MDA-6 (CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1) cyclin-dependent kinase inhibitor 1C; cyclin-dependent kinase inhibitor p57; p57KIP2 (CDKN1C KIP2) cyclin-dependent kinase inhibitor 2B-related protein; p15INK4B-related protein (P15RS, RPRD1A) cyclin-dependent kinase inhibitor 3; CDK2-associated dual-specificity phosphatase; kinase-associated phosphatase; cyclin-dependent kinase-interacting protein 2; cyclin-dependent kinase interactor 1 (CDKN3, CDI1, CIP2, KAP) p16ink4A; cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; cyclin-dependent kinase 4 inhibitor A; CDK4I; p16-INK4a; p16INK4A; p16-INK4; multiple tumor suppressor 1; MTS-1; p16MTS1 (CDKN2A, CDKN2, MTS1) p27KIP1; cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor p27 (CDKN1B, KIP1) palbociclib (Ibrance) ribociclib (Kisqali) trilaciclib (Cosela)